Pancreatic Cancer Research

ResearcherInsermActive in the last 2 years

António Sá Cunha

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4015-5368; OpenAlex author ID A5070118413. Sources: OpenAlex.

Their work

Papers
29 (first author 2, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
130
Papers, trials and grants by year

2014: 1 paper · 2015: 4 papers · 2016: 1 paper · 2017: 2 papers · 2018: 3 papers · 2019: 3 papers · 2020: 1 paper · 2021: 3 papers · 2022: none · 2023: 2 papers · 2024: 3 papers · 2025: 4 papers · 2026: 2 papers

Papers 29

  1. Current practices and challenges in the management of nonmetastatic pancreatic adenocarcinoma: results of an EORTC survey. Co-author DOI 10.1016/j.esmogo.2026.100372↗
  2. International survey on neoadjuvant treatments in anatomically resectable pancreatic adenocarcinoma (INSPIRA): a real-life snapshot. Co-author DOI 10.1016/j.suronc.2026.102580↗
  3. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  4. Minimally Invasive vs Open Left Pancreatectomy for Resectable Pancreatic Cancer: Long-Term Results of the Randomized DIPLOMA Trial. Co-author DOI 10.1001/jamasurg.2025.4054↗
  5. Validation of the PANAMA Score for Survival and Benefit of Adjuvant Therapy in Patients With Resected Pancreatic Cancer after Neoadjuvant FOLFIRINOX. Co-author DOI 10.1097/sla.0000000000006650↗
  6. Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PROD… Co-author DOI 10.1200/jco-24-01378↗
  7. Splenic vein tumor thrombosis is a major prognostic factor in distal pancreatic adenocarcinoma. Co-author DOI 10.1016/j.surg.2023.10.028↗
  8. Influence of pancreatic fistula on survival after upfront pancreatoduodenectomy for pancreatic ductal adenocarcinoma: multicentre retrospective study. Co-author DOI 10.1093/bjsopen/zrae125↗
  9. New Biomarkers to Define a Biological Borderline Situation for Pancreatic Adenocarcinoma: Results of an Ancillary Study of the PANACHE01-PRODIGE48 Trial. Co-author DOI 10.1097/sla.0000000000006468↗
  10. Minimally invasive versus open distal pancreatectomy for resectable pancreatic cancer (DIPLOMA): an international randomised non-inferiority trial. Co-author DOI 10.1016/j.lanepe.2023.100673↗
  11. Surgical and Oncological Outcomes After Preoperative FOLFIRINOX Chemotherapy in Resected Pancreatic Cancer: An International Multicenter Cohort Study. Co-author DOI 10.1245/s10434-022-12387-2↗
  12. Laparoscopic versus open extended radical left pancreatectomy for pancreatic ductal adenocarcinoma: an international propensity-score matched study. Co-author DOI 10.1007/s00464-020-08206-y↗
  13. Local treatment of pancreatic cancer metastases: A multicenter French study of the AGEO group. Co-author DOI 10.1016/j.clinre.2020.101607↗
  14. Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: update of the AGEO cohort. Co-author DOI 10.1038/s41416-021-01341-w↗
  15. Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment. Co-author DOI 10.1001/jamaoncol.2020.3537↗
  16. Characteristic and outcomes of patients with pathologic complete response after preoperative treatment in borderline and locally advanced pancreatic adenocarci… Co-author DOI 10.1016/j.clinre.2019.03.007↗
  17. "Laparoscopic Para-Aortic Lymph Node Sampling" First Approach for Pancreatic Adenocarcinoma as an Oncological Practice. Last author DOI 10.1089/lap.2018.0775↗
  18. How Does Chemoradiotherapy Following Induction FOLFIRINOX Improve the Results in Resected Borderline or Locally Advanced Pancreatic Adenocarcinoma? An AGEO-FRE… Last author DOI 10.1245/s10434-018-6931-6↗
  19. Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC). Co-author DOI 10.1016/j.dld.2018.08.008↗
  20. Severe postoperative complications decrease overall and disease free survival in pancreatic ductal adenocarcinoma after pancreaticoduodenectomy. Co-author DOI 10.1016/j.ejso.2018.03.024↗
  21. Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODI… Last author DOI 10.1186/s12885-018-4663-4↗
  22. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma. Co-author DOI 10.1007/s00330-016-4632-8↗
  23. Pancreatic adenocarcinoma: A simple CT score for predicting margin-positive resection in patients with resectable disease. Co-author DOI 10.1016/j.ejrad.2017.06.028↗
  24. Radiological evaluation of response to neoadjuvant treatment in pancreatic cancer. First author DOI 10.1016/j.diii.2016.07.011↗
  25. Severe Jaundice Increases Early Severe Morbidity and Decreases Long-Term Survival after Pancreaticoduodenectomy for Pancreatic Adenocarcinoma. Co-author DOI 10.1016/j.jamcollsurg.2015.03.058↗
  26. FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort. First author DOI 10.1245/s10434-014-3898-9↗
  27. Pancreatic adenocarcinoma with venous involvement: is up-front synchronous portal-superior mesenteric vein resection still justified? A survey of the Associati… Co-author DOI 10.1245/s10434-014-4304-3↗
  28. Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-… Co-author DOI 10.1245/s10434-015-4783-x↗
  29. Locally advanced pancreatic adenocarcinoma: reassessment of response with CT after neoadjuvant chemotherapy and radiation therapy. Co-author DOI 10.1148/radiol.14132914↗

Closest collaborators

The 25 strongest of 130 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jean‐Baptiste Bachet · 10 shared papers, 2015–2024 · strength 0.96
  2. Alain Sauvanet Sauvanet · 6 shared papers, 2015–2024 · strength 0.61
  3. F. Huguet · 3 shared papers, 2018–2026 · strength 0.49
  4. Daniel Pietrasz · 6 shared papers, 2015–2025 · strength 0.49
  5. Lilian Schwarz · 4 shared papers, 2018–2024 · strength 0.47
  6. L. Chiche · 6 shared papers, 2014–2024 · strength 0.46
  7. Olivıer Turrini · 5 shared papers, 2015–2024 · strength 0.42
  8. Cindy Neuzillet · 2 shared papers, 2018–2026 · strength 0.42
  9. Christophe Laurent · 5 shared papers, 2014–2024 · strength 0.40
  10. Julien Taı̈eb · 6 shared papers, 2015–2021 · strength 0.39
  11. Romain Coriat · 5 shared papers, 2015–2021 · strength 0.36
  12. Matthieu Delaye · 1 shared paper, 2026 · strength 0.36
  13. Ingrid Garajová · 1 shared paper, 2026 · strength 0.36
  14. Christelle Bouchart · 1 shared paper, 2026 · strength 0.36
  15. Sébastien Gaujoux · 3 shared papers, 2018–2024 · strength 0.32
  16. Frédéric Di Fiore · 2 shared papers, 2019–2024 · strength 0.31
  17. Déwi Vernerey · 2 shared papers, 2018–2024 · strength 0.31
  18. Alberto Balduzzi · 3 shared papers, 2020–2025 · strength 0.31
  19. Tobias Keck · 3 shared papers, 2020–2025 · strength 0.31
  20. Adnan A. Alseidi · 3 shared papers, 2020–2025 · strength 0.31
  21. Frederik Christiaan Berrevoet · 3 shared papers, 2020–2025 · strength 0.31
  22. Thilo Hackert · 3 shared papers, 2020–2025 · strength 0.31
  23. Giovanni Butturini · 3 shared papers, 2020–2025 · strength 0.31
  24. Bas Groot Koerkamp · 3 shared papers, 2020–2025 · strength 0.31
  25. Marc G. Besselink · 3 shared papers, 2020–2025 · strength 0.31

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.